Topical ENS-002 for Atopic Dermatitis in Adults

Summary

The goal of this study is to determine the safety and effects of ENS-002, a live biotherapeutic product (LBP) consisting of commensal, clonal, non-pathogenic bacteria in participants with atopic dermatitis.

Timeline

Start

2024-09-18

Primary completion

2025-08-04

Completion

2025-08-04

Outcome

Met primary endpoint

Stopped: “Planned safety, efficacy and proof of mechanism obtained”

release “ENS-002 was safe and well-tolerated with no drug-related adverse events, meeting its primary endpoint.” concertobio.com ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ENS-002	Other / unclassified	—	Topical

Indications